PMID- 24142614
OWN - NLM
STAT- MEDLINE
DCOM- 20140430
LR  - 20201209
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 19
DP  - 2013 Oct
TI  - The influence of angiotensin-converting enzyme 2 gene polymorphisms on type 2 
      diabetes mellitus and coronary heart disease.
PG  - 2654-9
LID - 5337 [pii]
AB  - BACKGROUND: Diabetes mellitus is a chronic metabolic disorder that results from 
      various genetic and environmental factors, and type 2 diabetes mellitus (T2DM) 
      combined with coronary heart disease (CHD) is one of the most common chronic 
      complications in diabetes. AIM: To explore the correlation between the 
      polymorphism of angiotensin-converting enzyme 2 (ACE2) and T2DM combined with 
      CHD. PATIENTS AND METHODS: A total of 120 patients with T2DM and 93 patients with 
      T2DM and CHD were selected to participate in this study. And polymerase chain 
      reaction -restriction fragment length polymorphism (PCR-RFLP) was used to analyze 
      the polymorphism of G8790A in ACE2 gene. Meanwhile, the clinical, biochemical and 
      echocardiographic data were also analyzed. RESULTS: There was no significant 
      difference between T2DM group and T2DM combined with CHD group in genotype and 
      allele frequencies (p > 0.05). And for different genotypes, both groups had no 
      significant difference in the age, BMI, blood lipid, fasting blood glucose, EF 
      ratio, E/A ration, LVPWTd and LVEDd (p > 0.05). But for male patients in T2DM 
      combined with CHD group, the IVSTd, LVPWTd and urine protein level of allele G 
      were significantly higher than that of allele A with p values less than 0.01, 
      0.05 and 0.05, respectively. CONCLUSIONS: Genetic polymorphism of G8790A in ACE2 
      gene plays an important role on the pathogenesis of male patients with T2DM and 
      CHD by changing the levels of IVSTd, LVPWTd and urine protein. Therefore, our 
      results reveal the role of ACE2 polymorphism in the pathogenesis of T2DM with CHD 
      and identify several potential biomarkers for this disease.
FAU - Chaoxin, J
AU  - Chaoxin J
AD  - Department of Clinical Laboratory, the Third People's Hospital, Nanhai District, 
      Foshan City, Guangdong, China. jiangchaoxinchx@hotmail.com.
FAU - Daili, S
AU  - Daili S
FAU - Yanxin, H
AU  - Yanxin H
FAU - Ruwei, G
AU  - Ruwei G
FAU - Chenlong, W
AU  - Chenlong W
FAU - Yaobin, T
AU  - Yaobin T
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
RN  - EC 3.4.17.23 (ACE2 protein, human)
RN  - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
SB  - IM
CIN - Eur Rev Med Pharmacol Sci. 2014;18(12):1685. PMID: 24992604
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme 2
MH  - Case-Control Studies
MH  - Coronary Disease/*genetics
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Echocardiography
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Peptidyl-Dipeptidase A/*genetics
MH  - *Polymorphism, Genetic
EDAT- 2013/10/22 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/10/22 06:00
PHST- 2013/10/22 06:00 [entrez]
PHST- 2013/10/22 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 5337 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 Oct;17(19):2654-9.